Aradigm Announces Completion of Patient Enrollment for Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis, News
Aradigm Corporation, a pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases, recently announced the conclusion of patient enrollment in the ... Read more